Ratings by JPMorgan (Cory Kasimov)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/25/2022 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/21/2022 | Acadia Pharmaceuticals | ACAD | Downgrade | Neutral (Overweight) |
19.51 (25.97) |
33.11% | Details | |
| 6/15/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (N/A) |
|
Details | ||
| 2/11/2022 | Ultragenyx Pharma | RARE | Upgrade | Overweight (Neutral) |
74.75 (33.47) |
-55.22% | Details | |
| 1/27/2022 | Vertex | VRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/5/2022 | Cerevel Therapeutics | CERE | New Coverage | Overweight (N/A) |
34.49 (44.96) |
30.36% | Details | |
| 11/19/2021 | bluebird bio | BLUE | Maintain | Neutral (N/A) |
|
Details | ||
| 11/19/2021 | Legand Biotech Corp. | LEGN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/28/2021 | NovoCure Ltd. | NVCR | Maintain | Neutral (N/A) |
|
Details | ||
| 9/30/2021 | Karuna Therapeutics Inc. | KRTX | New Coverage | Overweight (N/A) |
118.69 (329.83) |
177.89% | Details | |
| 8/9/2021 | bluebird bio | BLUE | Maintain | Neutral (N/A) |
|
Details | ||
| 8/5/2021 | Sana Biotechnology | SANA | Maintain | Neutral (N/A) |
|
Details | ||
| 8/5/2021 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (N/A) |
|
Details | ||
| 7/28/2021 | Alkermes | ALKS | Maintain | Neutral (N/A) |
|
Details | ||
| 7/22/2021 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 7/20/2021 | Moderna | MRNA | Maintain | Neutral (N/A) |
|
Details | ||
| 6/11/2021 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 6/1/2021 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 5/11/2021 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/1/2021 | Sana Biotechnology | SANA | New Coverage | Neutral (N/A) |
32.05 (4.02) |
-87.46% | Details | |
| 2/25/2021 | Moderna | MRNA | Maintain | Neutral (N/A) |
|
Details | ||
| 2/25/2021 | Editas Medicine | EDIT | Downgrade | Underweight (Neutral) |
49.70 (3.65) |
-92.66% | Details | |
| 2/17/2021 | bluebird bio | BLUE | Downgrade | Neutral (Overweight) |
45.76 (4.97) |
-89.14% | Details | |
| 2/12/2021 | Ultragenyx Pharma | RARE | Downgrade | Neutral (Overweight) |
162.78 (33.47) |
-79.44% | Details | |
| 2/11/2021 | Alkermes | ALKS | Maintain | Neutral (N/A) |
|
Details | ||
| 2/5/2021 | Regeneron Pharma | REGN | Maintain | Neutral (N/A) |
|
Details | ||
| 8/19/2020 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/13/2020 | Moderna | MRNA | Maintain | Neutral (N/A) |
|
Details | ||
| 8/11/2020 | BioNTech | BNTX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/5/2020 | Regeneron Pharma | REGN | Maintain | Neutral (N/A) |
|
Details | ||
| 8/5/2020 | Allogene | ALLO | Maintain | Neutral (N/A) |
|
Details | ||
| 8/4/2020 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 7/30/2020 | Alexion Pharmaceuticals | ALXN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/30/2020 | NovoCure Ltd. | NVCR | Maintain | Neutral (N/A) |
|
Details | ||
| 7/20/2020 | Moderna | MRNA | Downgrade | Neutral (Overweight) |
94.85 (79.76) |
-15.91% | Details | |
| 7/1/2020 | Legand Biotech Corp. | LEGN | New Coverage | Overweight (N/A) |
41.10 (29.91) |
-27.23% | Details | |
| 5/11/2020 | bluebird bio | BLUE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2020 | Incyte | INCY | Downgrade | Neutral (Overweight) |
100.99 (116.86) |
15.71% | Details | |
| 5/5/2020 | Regeneron Pharma | REGN | Maintain | Neutral (N/A) |
|
Details | ||
| 5/1/2020 | Gilead Sciences | GILD | Downgrade | Neutral (Overweight) |
84.00 (131.27) |
56.27% | Details | |
| 3/26/2020 | bluebird bio | BLUE | Maintain | Overweight (N/A) |
|
Details | ||
| 3/18/2020 | BioNTech | BNTX | Downgrade | Neutral (Overweight) |
40.00 (97.55) |
143.88% | Details | |
| 2/26/2020 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 2/14/2020 | Alkermes | ALKS | Maintain | (N/A) |
|
Details | ||
| 2/14/2020 | Alkermes | ALKS | Downgrade | Neutral (Overweight) |
19.10 (54.58) |
185.76% | Details | |
| 11/4/2019 | BioNTech | BNTX | New Coverage | Overweight (N/A) |
16.82 (97.55) |
479.96% | Details | |
| 10/24/2019 | Acorda Therapeutics, Inc. | ACOR | Downgrade | Underweight (Neutral) |
2.42 (0.66) |
-72.73% | Details | |
| 10/23/2019 | Alkermes | ALKS | Maintain | Overweight (N/A) |
|
Details | ||
| 9/10/2019 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (N/A) |
|
Details | ||
| 7/26/2019 | NovoCure Ltd. | NVCR | Downgrade | Neutral (Overweight) |
70.99 (17.20) |
-75.77% | Details | |
| 5/7/2019 | GW Pharma | GWPH | Maintain | Overweight (N/A) |
|
Details | ||
| 3/21/2019 | Biogen | BIIB | Downgrade | Neutral (Overweight) |
320.59 (216.12) |
-32.59% | Details | |
| 1/2/2019 | Moderna | MRNA | New Coverage | Overweight (N/A) |
15.27 (94.85) |
521.15% | Details | |
| 1/2/2019 | GW Pharma | GWPH | New Coverage | Overweight (N/A) |
97.39 (218.96) |
124.83% | Details | |
| 11/14/2018 | Jounce Therapeutics | JNCE | Downgrade | Underweight (Neutral) |
4.46 (1.88) |
-57.85% | Details | |
| 11/2/2018 | Puma Biotechnology | PBYI | Downgrade | Underweight (Neutral) |
38.60 (8.26) |
-78.6% | Details | |
| 10/31/2018 | Clovis Oncology | CLVS | Downgrade | Neutral (Overweight) |
16.70 (0.08) |
-99.52% | Details | |
| 10/2/2018 | Clovis Oncology | CLVS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/29/2018 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details |
